Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution.


Surmell Z. G. , Aksoy S., Dizdar O. , Dede D. S. , Dogan E., Arslan C., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.28, sa.15, 2010 (SCI İndekslerine Giren Dergi) identifier